Journey Medical Corp
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE, AZ, 85258
Mailing Address
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE, AZ, 85258
Phone
480-434-6670
Fiscal Year End
1231
EIN
471879539
Financial Overview
FY2025 FY
$61.86M
Revenue
-$11.43M
Net Income
$94.59M
Total Assets
$62.74M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | April 6, 2026 | View on SEC |
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | January 15, 2026 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 8-K Current report of material events | November 12, 2025 | View on SEC |
| 8-K Current report of material events | September 26, 2025 | View on SEC |
| 8-K Current report of material events | August 28, 2025 | View on SEC |
| 4 Insider stock transaction report | August 26, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | August 14, 2025 | View on SEC |
Annual Reports
10-K
March 26, 2026
- FDA approval of Emrosi in April 2024 offers a potential blockbuster growth catalyst.
- Revenue grew 8.3% year-over-year to $128.5 million.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.